Millrud Camilla Rydberg, Bergenfelz Caroline, Leandersson Karin
Department of Translational Medicine, Cancer Immunology, Lund University, Skåne University Hospital, Malmö, Sweden.
Department of Translational Medicine, Division of Experimental Infection Medicine, Lund University, Malmö, Sweden.
Oncotarget. 2017 Jan 10;8(2):3649-3665. doi: 10.18632/oncotarget.12278.
Myeloid-derived suppressor cells (MDSCs) have a strong immunosuppressive character that allows them to regulate immune responses and hinder overt inflammatory responses. In cancer, this leads to tumor immune evasion and disease progression. MDSCs come in at least two forms: monocytic (Mo-MDSCs) and granulocytic (G-MDSCs). The classical definition of MDSCs as immature myeloid cells blocked from differentiating has been challenged by recent studies suggesting that Mo-MDSCs and G-MDSCs may represent monocytes and granulocytes that have acquired immunosuppressive properties. The molecular mechanism behind their generation and their true origins are now widely debated. In this review we discuss the different proposed mechanisms of the generation of both types of MDSCs, with a special focus on human MDSCs in cancer.
髓系来源的抑制细胞(MDSCs)具有强大的免疫抑制特性,使其能够调节免疫反应并抑制过度的炎症反应。在癌症中,这会导致肿瘤免疫逃逸和疾病进展。MDSCs至少有两种形式:单核细胞样(Mo-MDSCs)和粒细胞样(G-MDSCs)。MDSCs作为受阻于分化的未成熟髓系细胞的经典定义,已受到最近研究的挑战,这些研究表明Mo-MDSCs和G-MDSCs可能代表已获得免疫抑制特性的单核细胞和粒细胞。它们产生背后的分子机制及其真正来源目前存在广泛争议。在这篇综述中,我们讨论了两种类型MDSCs产生的不同提出机制,特别关注癌症中的人类MDSCs。